Compare KeyCorp (KEY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Zimmer Biomet Holdings Inc — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KEY | ZBH | |
|---|---|---|
Market Cap | $21.45B | $16.95B |
Volume | 19,450,846 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $23.99 | $103.98 |
52-Week Low | $16.78 | $79.58 |
Typical Hold Time | 66 Days | 89 Days |
Enterprise Value | $34.63B | $24.02B |
Dividend Yield | 4.08% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.1, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly EPS beats. Recent news includes a prime rate hike to 7.00% and executive appointments, while the dividend remains frozen.
The outlook is mixed: analyst consensus is bullish with a $25.00 price target, but technical weakness and competitive dividend pressures pose risks. Revenue growth and share buybacks support upside, yet interest rate sensitivity and margin pressures require monitoring for sustained performance.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
